Evidence points to a lack of efficacy of ATRA-based therapy in non-APL AML as a result, at least in part, of a failure of ATRA to induce proper transcriptional activation of epigenetically repressed genes in the RARα-driven myeloid differentiation pathway (Schenk et al., 2012). This evidence concerns the gene RARA and acute myeloid leukemia.